Physician profile
Julie A Letsinger
NPI 1871541565
$1,305.21
in general payments reported to CMS, 2019-2025
13 companies · $705 in 2025
The $705 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.00 · 2020: $78.72 · 2023: $34.62 · 2024: $394 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852 · Education: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.90 |
| Education | $281.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $306.12 | 2019-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $184.14 | 2019-2025 | |
| Ucb, INC. | $166.66 | 2024 | Bimzelx |
| Incyte Corporation | $107.86 | 2024-2025 | Opzelura |
| Lilly USA, LLC | $90.99 | 2019-2025 | Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $87.24 | 2025 | Zoryve |
| Abbvie INC. | $75.66 | 2019-2024 | |
| Amgen INC. | $72.42 | 2024-2025 | Otezla, Otezla |
| Organon LLC | $63.71 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $47.98 | 2020-2024 | |
| Galderma Laboratories, L.P. | $46.48 | 2024-2025 | Nemluvio |
| Pfizer INC. | $35.03 | 2023-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.92 | 2024 | Cabtreo, Arazlo, Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Letsinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.